Fenwick represented MRL Ventures, the therapeutics-focused corporate venture fund of Merck & Co., Inc., in its participation in Ray Therapeutics’ $100 million Series A financing. The round was led by Novo Holdings A/S, with additional participation from Deerfield Management, Norwest Venture Partners, Platanus, and 4BIO Capital.
The funding will advance Ray Therapeutics’ optogenetics gene therapy programs for blinding retinal diseases. More information can be obtained from the company's announcement.
The Fenwick transaction team included corporate partner Ian Goldstein and was led by corporate partner Jonathan Sagot and associate Terence Desouza.